AOD-9604 Side Effects: What the Trials Reported and What to Watch For

The medication this page covers:

The price is all-in: medication, physician review, refill management and shipping, with no membership fee. AOD-9604 at Pepti is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved, and AOD-9604 has no FDA-approved product of any kind.

Most compounded peptides have no human trials at all. AOD-9604 has six. Between roughly 2001 and 2007 its developer, the Australian company Metabolic Pharmaceuticals, ran randomised, double-blind, placebo-controlled trials enrolling close to 900 people, mostly with obesity. The trials were designed to test weight loss, and the largest, OPTIONS, did not find statistically significant weight loss over placebo. But they produced a safety record, which a 2013 paper in the Journal of Endocrinology and Metabolism, written by people connected to the company, summarised across all six.

What that record reported:

• Adverse events similarly distributed between AOD-9604 and placebo.
• No change in IGF-1, the growth factor that growth hormone raises.
• No impairment of glucose tolerance.
• No anti-AOD-9604 antibodies detected in the subjects tested.
• No serious adverse event judged related to treatment.

Metabolic Pharmaceuticals also ran chronic oral toxicology in rats and monkeys and genotoxicity assays, and reported no concern. The FDA's reviewers read the same package as inconclusive because the published summary lacked data tables.

Several effects people worry about with growth hormone did not show up with AOD-9604. It is a fragment of growth hormone, not growth hormone itself, and it is not a secretagogue.

The water retention, joint aches and tingling hands associated with growth hormone secretagogues are not part of AOD-9604's reported profile. If you take AOD-9604 inside the SHRED or PHYSIQ blends, the other peptides in the vial do act on the growth hormone axis and bring their own side effects; see below.

The FDA's reviewers went through AOD-9604's safety record in 2024, ahead of the advisory committee vote on 4 December 2024 that went 0 to 12 against adding it to the 503A Bulks List for obesity. Two points from that review are worth knowing.

The cancers in the 300-patient study. Five serious adverse events in the 12-week oral study were cancers of various types. The investigators judged them unrelated to treatment, and none occurred in the highest-dose group. The FDA noted that the published summary did not contain enough detail to confirm that judgement either way. That is not evidence that AOD-9604 causes cancer; it is a gap in the record.

The injected route has never been tested. No human trial has used subcutaneous AOD-9604. The FDA's general concern about injected peptides, that they can provoke an immune response and that peptide impurities and aggregation add to that risk, applies here as it does to every compounded peptide injection. When AOD-9604 sat in Category 2 of the FDA's interim 503A list in 2023, the stated concerns were immunogenicity risk for certain routes, peptide impurities and characterisation, limited safety information, and serious adverse events possibly associated with the peptide without clear causality. It left Category 2 on 27 September 2024 when the nominations were withdrawn.

Those concerns are the reason the pharmacy matters. Lot test results for Pepti's medications are published at /quality/lab-results.

Because there is no interaction list, the intake asks for every medication and supplement you take, and a physician reviews it rather than a form. Anything that lowers blood sugar matters most, given the low blood sugar recorded in the intravenous studies.

Message your care team, through your account, if:

• Injection-site redness, swelling or soreness spreads, gets worse, or does not settle within a few days.
• Headache, dizziness, fatigue, nausea or diarrhea persists.
• You notice shakiness, sweating or confusion that could be low blood sugar, especially if you take insulin or another glucose-lowering medication. Treat it first, then report it.
• You become pregnant or are planning a pregnancy.
• You start any new medication or supplement.
• Your label and your syringe seem not to match. Do not inject; ask first.

Do not change your own dose in response to a side effect. Your physician sets your directions after reviewing how you are doing, and any new directions are printed on the next label.

Call 911 or go to the nearest emergency department for:

• Swelling of the face, lips, tongue or throat.
• Trouble breathing or swallowing.
• A widespread rash or hives with feeling faint.
• Any reaction that is severe or spreading quickly.

Get emergency care first, then tell your physician.

AOD-9604 is also prescribed inside two blends, and in a blend the side effects are those of every peptide in the vial.

Fluid retention, joint aches and hand tingling are classic growth hormone effects and usually mean the dose is higher than the person needs; they come from the secretagogues, not from AOD-9604. Tesamorelin also reduces insulin sensitivity, so existing diabetes or borderline glucose needs discussing before PHYSIQ. MOTS-c is associated with transient jitteriness, a faster pulse or mild light-headedness after a dose, mostly early in a course. No study has tested either blend as a blend. More in what is SHRED and what is PHYSIQ.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. Athletes should read peptides for athletes and do peptides show up on a drug test.

AOD-9604 has a cleaner and better documented safety record than most compounded peptides, because six randomised trials were run. Across them, adverse events looked similar to placebo, IGF-1 and glucose tolerance were unaffected, and no antibodies were detected. The limits are real: the trials used oral and intravenous dosing, not injection; the longest lasted 24 weeks; the main safety summary was written by people connected to the developer; and the FDA's reviewers found parts of the record too thin to confirm. A clean safety record is also not evidence that the peptide does what it is prescribed for, and the largest trial found no significant weight loss over placebo. The benefits picture is in AOD-9604 benefits, and the general guide is peptide side effects: what to watch for.

AOD-9604 cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration, which are the very things the FDA's injected-peptide concerns are about. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and dose questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance. The step-by-step page is how to get AOD-9604 prescribed online, and the dose arithmetic is in AOD-9604 dosage.